Tempus AI completed an $81.3 million stock-based acquisition of Paige, a digital pathology innovator known for developing the first FDA-cleared AI application in pathology diagnostics. The deal supplements Tempus’ oncology portfolio by integrating Paige’s extensive dataset of nearly seven million digitized pathology slides and proprietary AI models. This strategic expansion aims to enhance early cancer detection capabilities and accelerate drug discovery by leveraging advanced computational pathology across diverse patient populations.